Coloplast reports growth across all business areas

Coloplast generated revenues of DKK 5,707 million and 6% organic growth in the first six months of the financial year 2012/13.

 

Coloplast generated revenues of DKK 5,707 million and 6% organic growth in the first six months of the financial year 2012/13.EBIT was up 20% to DKK 1,756 million.

The EBIT margin was 31% against 27% in H1 2011/12. The net profit for the reporting period was up by 25% to DKK 1,252 million.

“We're reporting a strong performance in our first half-year report today. We're growing across all business areas and all regions, and I'm very pleased with our performance, which is in line with our guidance,” said Coloplast CEO Lars Rasmussen.

Sales growth by business area was as follows: Ostomy Care 6%, Continence Care 6%, Urology Care 9% and Wound & Skin Care 3%.

"I am particularly pleased with our sales performance in the Wound & Skin Care business area and I'm also very satisfied with the generally positive sales developments in Emerging Markets that support our ambitions for increasing our growth.”

 

Extraordinary dividends

Based on the half-year report, the Board of Directors has resolved to exercise the authorisation to pay extraordinary dividends provided by the shareholders at the annual general meeting held on 11 December 2012. Accordingly, Coloplast will pay an extraordinary dividend of DKK 3 per share for a total dividend payout of DKK 634 million.

“I'm very pleased that value creation in our company has been so strong that we're able to pay extraordinary dividends of more than half a billion Danish kroner,” says Lars Rasmussen.

For further information, click here to read the half-year report.